🇺🇸 FDA
Pipeline program

Placebo for AZP-3601 Pen A and Pen B, AZP-3601, CALCIUM ARROW 500 mg, comprimé à sucer, AZP-3601, UN-ALFA 0,50 microgramme, capsule molle, ROCALTROL 0,25 microgramme, capsule molle

AZP-3601-CLI-002

Phase 3 small_molecule active

Quick answer

Placebo for AZP-3601 Pen A and Pen B, AZP-3601, CALCIUM ARROW 500 mg, comprimé à sucer, AZP-3601, UN-ALFA 0,50 microgramme, capsule molle, ROCALTROL 0,25 microgramme, capsule molle for Hypoparathyroidism is a Phase 3 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).

Program details

Company
Alexion Europe SAS
Indication
Hypoparathyroidism
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials